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Abstract
Background: At present, palliative systemic chemotherapy is the standard treatment in the Netherlands for gastric
cancer patients with peritoneal dissemination. In contrast to lymphatic and haematogenous dissemination,
peritoneal dissemination may be regarded as locoregional spread of disease. Administering cytotoxic drugs directly
into the peritoneal cavity has an advantage over systemic chemotherapy since high concentrations can be
delivered directly into the peritoneal cavity with limited systemic toxicity. The combination of a radical gastrectomy
with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has shown promising
results in patients with gastric cancer in Asia. However, the results obtained in Asian patients cannot be
extrapolated to Western patients.
The aim of this study is to compare the overall survival between patients with gastric cancer with limited peritoneal
dissemination and/or tumour positive peritoneal cytology treated with palliative systemic chemotherapy, and those
treated with gastrectomy, CRS and HIPEC after neoadjuvant systemic chemotherapy.
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Methods: In this multicentre randomised controlled two-armed phase III trial, 106 patients will be randomised (1:1)
between palliative systemic chemotherapy only (standard treatment) and gastrectomy, CRS and HIPEC
(experimental treatment) after 3–4 cycles of systemic chemotherapy.Patients with gastric cancer are eligible for
inclusion if (1) the primary cT3-cT4 gastric tumour including regional lymph nodes is considered to be resectable,
(2) limited peritoneal dissemination (Peritoneal Cancer Index < 7) and/or tumour positive peritoneal cytology are
confirmed by laparoscopy or laparotomy, and (3) systemic chemotherapy was given (prior to inclusion) without
disease progression.
Discussion: The PERISCOPE II study will determine whether gastric cancer patients with limited peritoneal
dissemination and/or tumour positive peritoneal cytology treated with systemic chemotherapy, gastrectomy, CRS
and HIPEC have a survival benefit over patients treated with palliative systemic chemotherapy only.
Trial registration: clinicaltrials.gov NCT03348150; registration date November 2017; first enrolment November 2017;
expected end date December 2022; trial status: Ongoing.
Keywords: Hyperthermic intraperitoneal chemotherapy, HIPEC, Peritoneal metastasis, Peritonitis carcinomatosa,
Gastric cancer, Cytoreductive surgery, Palliative systemic chemotherapy, Gastrectomy, Surgery
Background
Gastric cancer has an aggressive natural behaviour, with
40% of the patients having metastatic disease at the time
of diagnosis [1]. The peritoneum is a predilection site
for tumour dissemination and is synchronously affected
in 14% of all patients. Around 9% of the patients have
peritoneal dissemination without other metastatic locali-
sations. The prognosis of patients with peritoneal dis-
semination is dismal, with a median overall survival of
only 3–4months [1, 2].
Systemic therapy is less effective in patients with periton-
eal dissemination compared to patients with metastases in
other locations [3–5]. Administering cytotoxic drugs into
the peritoneal cavity offers several advantages over systemic
chemotherapy. Firstly, high concentrations can be delivered
directly into the peritoneal cavity with limited systemic tox-
icity [6]. Secondly, heating enhances the cytotoxicity of
some agents (e.g. cisplatin and oxaliplatin) [7, 8]. Rat
models have shown enhanced tumour penetration in intra-
peritoneal tumour deposits if chemotherapeutic agents are
administered intraperitoneally compared to intravenously
[9]. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
has proven its therapeutic efficacy in patients with periton-
eal dissemination from several cancer types, e.g. colon can-
cer and ovarian cancer [10–12]. For patients with
peritoneal dissemination from gastric cancer there is data,
primarily Asian, suggesting that intraperitoneal chemother-
apy combined with gastrectomy and cytoreductive surgery
(CRS) may improve survival [13–15].
Previously, our study group conducted a phase I-II
dose-escalation trial (PERISCOPE I) to study safety and
feasibility of a procedure combining gastrectomy, CRS
and HIPEC with oxaliplatin (41-42 °C) followed by doce-
taxel (37 °C) [16]. In a strictly selected group of patients,
the treatment was safe and feasible with an intraperito-
neal dose of 460 mg/m2 oxaliplatin followed by 50 mg/
m2 docetaxel after the evolvement of a stringent
post-operative care protocol [17]. In the Netherlands,
the Ministry of Health appointed this novel approach as
highly innovative, having led to participation in the
Coverage with Evidence Development (CED) program.
Within this program, the gastric HIPEC procedure is
currently conditionally reimbursed by health insurance.
The primary objective of the present study is to com-
pare overall survival between gastric cancer patients with
limited peritoneal dissemination and/or tumour positive
peritoneal cytology treated with the current standard
treatment, i.e. palliative systemic chemotherapy, and
those treated with gastrectomy, CRS and HIPEC after
neoadjuvant systemic chemotherapy. Within the CED
program, the second objective of this study is to calcu-
late cost-effectiveness. If the experimental treatment
provides a survival benefit over the standard treatment,
health insurance coverage will be made unconditional.
Methods
Study design
The PERISCOPE II study is a multicentre randomised
controlled two-armed phase III trial (Fig. 1). After 3–4 cy-
cles of systemic chemotherapy, patients are randomly allo-
cated (1:1) to the standard treatment arm (continuing
palliative systemic chemotherapy) or to the experimental
treatment arm (gastrectomy, CRS and HIPEC). The study
protocol has been approved by the medical ethical com-
mittee of the Netherlands Cancer Institute-Antoni van
Leeuwenhoek Hospital. A research grant has been pro-
vided by The Netherlands Organisation for Health Re-
search and Development (ZonMW).
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Study population
Adult patients (18 years or older), with histologically
proven locally advanced (cT3-cT4, any N) adenocarcin-
oma or undifferentiated carcinoma of the stomach with
limited peritoneal dissemination and/or tumour positive
peritoneal cytology are eligible for participation. In this
trial, limited peritoneal dissemination is defined as a Peri-
toneal Cancer Index (PCI) below 7 [18–20]. At first, pa-
tients have to be treated with systemic chemotherapy.
Study candidates are included provided that the primary
gastric tumour is considered resectable, there is no disease
progression during systemic chemotherapy and distant
metastases are absent. A detailed list of the inclusion and
exclusion criteria can be found in the Additional file 1.
Sample size
Previous data have indicated that the median survival
time of patients with gastric cancer with peritoneal me-
tastasis is about 3–4 months [1]. It is expected that in
the experimental arm 75% of patients will receive proto-
col treatment and 25% of patients will be treated off
protocol due to gross peritoneal dissemination (PCI ≥ 7)
at the time of the laparotomy. It is hypothesised that the
median overall survival among the 75% of patients in the
experimental arm who actually undergo CRS and HIPEC
will be 12 months, while the other 25% of patients in the
experimental arm will have a median overall survival of
only 3 months.
A total of 106 patients, 53 in each arm, will be included
and followed until a total of 80 deaths is observed. Assum-
ing exponential survival with medians as described above
in each of the three groups, this will yield 90% power to
detect a difference in overall survival at the two-sided 95%
confidence level (intention-to-treat analysis).
In the Netherlands, around 200 patients per year are
diagnosed with gastric cancer and synchronous periton-
eal carcinomatosis without distant metastases [1]. At
least 60% of these patients will not be eligible for the
study because of co-existing diseases, poor condition,
irresectability of the gastric tumour and/or gross peri-
toneal tumour involvement. This leaves an estimated
number of 80 patients per year eligible for inclusion.
Next to that, around 5% of all newly diagnosed gastric
cancer patients who are found suitable for treatment
Fig. 1 PERISCOPE II study flowchart. HIPEC: Hyperthermic Intraperitoneal Chemotherapy
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with curative intent has tumour positive peritoneal cy-
tology [21, 22]. This group of patients, around 50 per year,
is also eligible for inclusion. It adds up to a total of 130 po-
tential study candidates per year in the Netherlands.
The expected accrual is around 35 patients per year.
Via the Dutch Upper GI Cancer Group (DUCG) all
medical oncologists and surgeons who treat patients
with gastric cancer are being informed on a regularly
basis about the study progress and referral issues. Patient
inclusion will take about 3 years. Thereafter, there will
be an additional follow-up period of 2 years, for a total
study period of 5 years.
Study procedures
Prior to inclusion: laparoscopy or laparotomy
Prior to inclusion all patients undergo a diagnostic lapar-
oscopy or laparotomy. During this procedure the extent
of peritoneal dissemination is assessed. The presence
and number of macroscopic tumour deposits are re-
corded according to the PCI (Fig. 2) [18].
Prior to inclusion: systemic chemotherapy and response
assessment
Patients are treated with systemic chemotherapy prior to
inclusion. Accepted chemotherapy regimens generally con-
sist of a platinum-drug combined with a fluoropyrimidine.
Additionally, an anthracycline or taxane can be added ac-
cording to the local protocol. Examples of accepted chemo-
therapy regimens are: docetaxel + oxaliplatin + 5-FU,
docetaxel + cisplatin + 5-FU, epirucibin + cisplatin + 5-FU,
epirucibin + oxaliplatin + 5-FU. In patients with a Her2
positive gastric tumour, trastuzumab can be added to the
combination of chemotherapeutic drugs.
Response assessment is done by a Computed Tomography
(CT)-scan after 2–3 courses. In the absence of disease pro-
gression, patients can be included. Response evaluation and
patient’s study inclusion are discussed in (local or regional)
multidisciplinary tumour board meetings.
Inclusion and randomisation
After written informed consent is obtained, the patient
is registered and randomised. Patients are randomised
centrally by computer and are stratified for centre (name
of hospital), main histological subtype (intestinal versus
diffuse) and for the extent of peritoneal dissemination
(macroscopic peritoneal tumour deposits versus tumour
positive peritoneal cytology only).
Treatment
Standard arm
After randomisation, patients included in the standard
arm continue treatment with systemic chemotherapy.
The treating physician determines which chemothera-
peutic regimen is used and the duration of the treat-
ment. Surgery in this arm is only performed to relieve
severe symptoms, such as a gastric outlet obstruction.
Experimental arm
If allocated to the experimental treatment arm, preferably
3–4 courses of systemic chemotherapy are given prior to
surgery, as is usual in the potentially curative setting for
gastric cancer. Within 4 weeks before the planned
Fig. 2 Peritoneal cancer index [18]
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operation an additional CT-scan is made. If there are still
no signs of tumour progression patients proceed to surgery.
Laparotomy Surgical approach is via a midline laparot-
omy. A thorough inspection of the peritoneal cavity is
performed. If ascites is found, representative samples are
obtained for cytological assessment. The presence and
number of macroscopic tumour deposits are recorded to
score the PCI (Fig. 2).
Gross peritoneal dissemination (PCI ≥7), small bowel
dissemination and/or an irresectable primary gastric
tumour preclude further study treatment. In these in-
stances, HIPEC is not performed and it is up to the sur-
geon to decide whether a palliative surgical intervention
is indicated.
Gastrectomy, cytoreductive surgery and HIPEC If a
potentially curative gastric cancer resection is possible and
the PCI is below 7, a (sub)total gastrectomy with D2 lymph-
adenectomy is performed. Patients with macroscopic peri-
toneal tumour deposits undergo CRS to leave no
macroscopic disease behind. Gastrointestinal continuity is re-
stored by either a Billroth II or Roux-en-Y reconstruction.
HIPEC is performed via 3 inflow and 2 outflow catheters
using an open abdominal technique under continuous cir-
culation. The peritoneal cavity is perfused with 460mg/m2
oxaliplatin (max 920mg) at an intraperitoneal temperature
of 41 °C to 42 °C. After 30min, the perfusion fluid is
drained from the abdomen and the peritoneal cavity is per-
fused with 50mg/m2 docetaxel (max 100mg) at an intra-
peritoneal temperature of 37 °C, for 90min. A feeding
jejunostomy catheter is inserted and will remain in situ
until oral intake is adequate. The three inflow catheters are
left in situ for postoperative drainage.
Postoperative care After surgery, all patients are admitted
to the Intensive Care Unit. Postoperative enteral feeding via
the jejunostomy catheter can start on the day of surgery at
a very low dosage (maximum 10 cc/hour). Besides that,
total parenteral nutrition is started on postoperative day 3.
When there are no (more) signs of a postoperative ileus,
oral feeding is introduced and enteral feeding via the jeju-
nostomy catheter is gradually increased.
Adjuvant treatment Adjuvant treatment is not part of
the standard study protocol but will be discussed in the
multidisciplinary tumour board meeting for all patients
included in the study. The decision is based upon the
patient’s individual intraoperative and pathological re-
sults, the response to and toxicity from neoadjuvant sys-
temic therapy, as well as the postoperative recovery.
Follow-up
All patients, including those patients whose treatment
has deviated from the study protocol, are seen at the
outpatient clinic every 3 months for 1.5 years and every
6 months thereafter until 3 years after randomisation.
Survival status and disease recurrence/progression are
assessed until death. Follow-up consists of physical
examination, diagnostic investigations (tumour markers
in blood samples and CT-scans) and registration of hos-
pital re-admission details (if applicable). Quality of life
(QoL) questionnaires are sent to the patient at 3, 9, 15,
24 and 36months after randomisation.
Safety
All adverse events and serious adverse events are recorded
until 100 days after randomisation (standard arm) or sur-
gery (experimental arm). To ensure quality of data, study
integrity and compliance with the protocol and the vari-
ous applicable regulations and guidelines, a data monitor
of the Netherlands Cancer Institute-Antoni van Leeuwen-
hoek Hospital has been appointed to conduct site visits to
the participating centres and randomly check patient data.
Data from all patients are also checked at the central data
centre of the Netherlands Cancer Institute-Antoni van
Leeuwenhoek Hospital. An independent safety monitoring
board including a statistician, surgeon and medical on-
cologist has been installed. After the first 20 patients have
completed 90 days of follow-up the safety monitoring
board will advise on the continuation of the study. This
procedure will be repeated after the inclusion of 40 pa-
tients with 90 days of follow-up.
Analysis
Study outcome parameters will be analysed using de-
scriptive statistical methods. Overall and disease-free
survival analyses will be performed by the Kaplan-Meier
method for all patients following the intention-to-treat
principle. A per-protocol analysis will be performed. In
these analyses, survival will be measured from the date
of randomisation to the date of disease recurrence and/
or death. An interim analysis for efficacy will be per-
formed when 40 deaths (i.e. half of the required number
of events) have been observed.
Cost-effectiveness analysis
The cost-effectiveness analysis will compare the costs
and health benefits of the standard treatment (palliative
systemic chemotherapy) to those of the experimental
treatment (including the HIPEC procedure). This ana-
lysis will include direct costs (surgery, HIPEC, diagnostic
work-up, treatment of recurrences, follow-up visits and
palliative care) and indirect costs such as productivity
losses. The primary outcome for health effects will be
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quality adjusted life years, measured by means of the
EuroQol 5D, being part of the study QoL questionnaires.
Responsibilities
Protocol modifications will be submitted as amendment
to the central medical ethical committee by the study
coordinator. Communication between the study centres,
the independent safety monitoring board and the data
monitor is coordinated by the study coordinator. Partici-
pating study centres are responsible for patient inclu-
sion, patient treatment, patient follow-up and data
collection in the central data portal. At least twice a year
a meeting will be organised for all relevant parties, i.e.,
the principle and local investigators, the trial sponsors,
the data monitor, and the study coordinator, to discuss
progress, problems and possible protocol modifications.
The study coordinator – together with the principle in-
vestigator - will have access to the final dataset and is re-
sponsible for publishing study results. The results will be
submitted to a peer-reviewed journal.
Discussion
Study rationale
The primary objective of the PERISCOPE II study is to
compare overall survival between patients with gastric
cancer with limited peritoneal dissemination and/or
tumour positive peritoneal cytology treated with the
current standard treatment, i.e. palliative systemic
chemotherapy and those treated with gastrectomy, CRS
and HIPEC, following systemic chemotherapy. In the
dose-escalation PERISCOPE I study the combination of
gastrectomy, CRS and HIPEC with oxaliplatin and doce-
taxel following systemic chemotherapy appeared safe
and feasible provided that the following aspects were ac-
knowledged [16, 17]. Firstly, the maximum dose of intra-
peritoneal docetaxel should not exceed 50mg/m2 [17].
Secondly, patients were selected according to strict in-
and exclusion criteria [16]. And, thirdly, to counteract
the frequent occurrence of ileus-related postoperative
complications, a stringent postoperative care protocol
has been implemented [23].
Patient selection
Complete cytoreduction is a key element in successful
HIPEC surgery. There is a clear relationship between the
probability to reach a complete cytoreduction and the
extent of peritoneal disease, i.e. the PCI [19]. In several
studies of patients with gastric cancer with peritoneal
metastasis treated with a HIPEC procedure, a PCI of 7
emerged as a cut-off value between patients with
long-term survival and those without [19, 20, 24]. There-
fore, in the PERISCOPE II study, a PCI below 7 has been
defined as inclusion criterion. It can be expected that
strict PCI criteria improve homogeneity of the included
study population.
Choice of intraperitoneal chemotherapy
Based on a comprehensive literature review a combination
of a platinum-based agent and a taxane was considered to
be the most promising for the intraperitoneal treatment of
peritoneal dissemination of gastric cancer origin [25]. Cis-
platin and oxaliplatin are both platinum-based chemother-
apeutic agents that are often used in HIPEC procedures.
For gastric cancer patients oxaliplatin seems favourable
for a number of reasons. Firstly, gastric cancer cell lines
are more sensitive to oxaliplatin than to cisplatin [26].
Secondly, systemic oxaliplatin appears to be superior, or at
least equal, in terms of overall and disease-free survival in
patients with gastric cancer [27, 28]. And, lastly, in con-
trast to cisplatin, oxaliplatin is not nephrotoxic.
The taxane docetaxel was chosen as second agent as it is
widely used in the systemic treatment of gastric cancer [29,
30]. It can be administered intraperitoneally, as shown in
Asian studies wherein catheter-based-intraperitoneal doce-
taxel had clinical efficacy with acceptable safety [13, 29].
Learning curve
HIPEC procedures in general have a steep learning curve
[31–33]. In the current trial, no more than 5 centres will
participate in the experimental treatment arm. These 5 cen-
tres were selected based on their experience in gastric can-
cer surgery and in HIPEC procedures for other indications
as well as on their geographic location in the Netherlands.
During the PERISCOPE I study, strict guidelines for
per-operative and postoperative care were defined. Consid-
ering the extensive experience of the participating centres
together with the strict guidelines, the learning curve in the
PERISCOPE II is expected to be negligible.
Cost effectiveness
Based on the costs and the quality-adjusted life years a
model can be drafted to estimate the financial impact of the
experimental treatment. This will provide governments
with a potential basis to draft legislation regarding cost au-
thorisation for the HIPEC procedure as a possible treat-
ment option in the management of gastric cancer patients.
Other HIPEC trials for gastric cancer
In the German GASTRIPEC trial (NCT02158988) gas-
trectomy and CRS are compared to gastrectomy, CRS and
HIPEC with mitomycin C and cisplatin in patients with
gastric cancer and synchronous peritoneal dissemination.
In the French GASTRCHIP trial (NCT01882933) gastrec-
tomy and HIPEC with oxaliplatin (250mg/m2) are com-
pared to gastrectomy only in patients with locally
advanced gastric cancer defined as cT3-cT4 with either se-
rosal invasion, tumour perforation, lymph node invasion
Koemans et al. BMC Cancer          (2019) 19:420 Page 6 of 8
or tumour positive peritoneal cytology [34]. The presence
of macroscopic peritoneal lesions is an exclusion criterion
in the GASTRICHIP trial. At present, the PERISCOPE II
trial is unique in comparing gastrectomy, CRS and HIPEC
with palliative systemic chemotherapy, which is the
current standard treatment for patients with gastric cancer
with peritoneal dissemination in the Netherlands.
Conclusion
The PERISCOPE II trial will determine whether patients
with gastric cancer with limited peritoneal dissemination
(PCI < 7) and/or tumour positive peritoneal cytology
treated with systemic chemotherapy followed by gastrec-
tomy, CRS and HIPEC have a survival benefit over those
treated with palliative systemic chemotherapy alone. The
study will provide data on survival, toxicity,
cost-effectiveness and quality of life in patients with gastric
cancer undergoing HIPEC surgery. The ultimate goal is to
define whether the HIPEC procedure can be used as a
standard treatment option for patients with gastric cancer
with limited peritoneal dissemination and/or tumour posi-
tive peritoneal cytology, provided that there was no disease
progression during neoadjuvant systemic chemotherapy.
Additional file
Additional file 1: Inclusion and exclusion criteria of the PERISCOPE II
trial. List of all in and exclusion criteria. (DOCX 19 kb)
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